【Golden Biotechnology】Announcement of the Board of Directors' Approval of the Financial Report for Q1 2026

Key facts

  • 【Golden Biotechnology】Announcement of the Board of Directors' Approval of the Financial Report for Q1 2026
  • Golden Biotechnology's Board of Directors approved its financial report for Q1 2026 on May 8, 2026. For the period from January 1 to March 31, operating revenue reached NT$6,278 thousand, net loss attributable to owners of the parent was NT$23,094 thousand, and basic earnings per share stood at (NT$0.36).
  • Source: PR Times
  • Date: May 8, 2026

Direct answer

Golden Biotechnology's Board of Directors approved its financial report for Q1 2026 on May 8, 2026. For the period from January 1 to March 31, operating revenue reached NT$6,278 thousand, net loss attributable to owners of the parent was NT$23,094 thousand, and basic earnings per share stood at (NT$0.36).

Citation
【Golden Biotechnology】Announcement of the Board of Directors' Approval of the Financial Report for Q1 2026 (May 8, 2026), PR Times
Source
PR Times
Date
May 8, 2026
Golden Biotechnology's Board of Directors approved its financial report for Q1 2026 on May 8, 2026. For the period from January 1 to March 31, operating revenue reached NT$6,278 thousand, net loss attributable to owners of the parent was NT$23,094 thousand, and basic earnings per share stood at (NT$0.36).
その他NQ 0/100出典:PR Times

📋 Article Processing Timeline

  • 📰 Published: May 8, 2026 at 09:00
  • 🔍 Collected: May 9, 2026 at 08:00 (23h 0m after Published)
  • 🤖 AI Analyzed: May 9, 2026 at 09:17 (1h 17m after Collected)
1. Date of reporting to or resolution by the Board of Directors: 2026/05/08
2. Date of approval by the Audit Committee: 2026/05/08
3. Reporting period for the financial report or annual self-compiled financial information:
From (YYYY/MM/DD) to (YYYY/MM/DD): 2026/01/01 to 2026/03/31
4. Operating revenue accumulated from January 1 to the current period (in thousands NTD): 6,278
5. Gross operating profit (or loss) accumulated from January 1 to the current period (in thousands NTD): 3,941
6. Operating income (or loss) accumulated from January 1 to the current period (in thousands NTD): (26,548)
7. Profit before tax (or loss) accumulated from January 1 to the current period (in thousands NTD): (23,094)
8. Net profit (or loss) for the current period accumulated from January 1 to the current period (in thousands NTD): (23,094)
9. Net profit (or loss) attributable to owners of the parent accumulated from January 1 to the current period (in thousands NTD): (23,094)
10. Basic earnings per share (or loss) accumulated from January 1 to the current period (NTD): (0.36)
11. Total assets at period end (in thousands NTD): 920,098
12. Total liabilities at period end (in thousands NTD): 77,100
13. Equity attributable to owners of the parent at period end (in thousands NTD): 842,998
14. Other matters that should be specified: None

FAQ

What are the key facts in this article?

Golden Biotechnology's Board of Directors approved its financial report for Q1 2026 on May 8, 2026. For the period from January 1 to March 31, operating revenue reached NT$6,278 thousand, net loss attributable to owners of the parent was NT$23,094 thousand, and basic earnings per share stood at (NT$0.36).

What is the direct answer?

Golden Biotechnology's Board of Directors approved its financial report for Q1 2026 on May 8, 2026. For the period from January 1 to March 31, operating revenue reached NT$6,278 thousand, net loss attributable to owners of the parent was NT$23,094 thousand, and basic earnings per share stood at (NT$0.36).

What is the source and date?

PR Times: https://mops.twse.com.tw/material/twse-6794-2026-05-08-455750fa | May 8, 2026